行情

SELB

SELB

Selecta生物科学
NASDAQ

实时行情|Nasdaq Last Sale

1.430
+0.020
+1.43%
交易中 14:31 11/19 EST
开盘
1.410
昨收
1.410
最高
1.450
最低
1.400
成交量
4.46万
成交额
--
52周最高
6.25
52周最低
1.280
市值
6,892.57万
市盈率(TTM)
-0.8992
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SELB 新闻

  • 分析师:iPhone 11需求强劲 获得“巨大”成功
  • 新浪财经.32分钟前
  • 无论谁赢得下月大选 英国将卷入新一波债务洪流
  • 新浪美股.35分钟前
  • 美国科技巨头反击美国议员反垄断担忧 回应来了
  • 新浪美股.45分钟前
  • 麻烦不断!电子烟巨头Juul因针对青少年推销再遭起诉
  • 新浪财经.2小时前

更多

所属板块

生物技术和医学研究
+2.24%
制药与医学研究
+0.79%

热门股票

名称
价格
涨跌幅

SELB 简况

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.
展开

Webull提供Selecta Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。